Breaking News Instant updates and real-time market news.

IMMU

Immunomedics

$15.50

-0.22 (-1.40%)

09:05
01/08/18
01/08
09:05
01/08/18
09:05

Immunomedics, Royalty Pharma announce royalty funding, stock purchase agreements

Immunomedics and Royalty Pharma announced that Immunomedics has agreed to sell tiered, sales-based royalty rights on global net sales of sacituzumab govitecan to Royalty Pharma for $175 million. Royalty Pharma has also purchased $75 million in common stock of Immunomedics, at $17.15 per share, which represents a more than 15% premium over the stock's 15-day trailing average closing price. This $250 million funding provides Immunomedics the resources to support the Company's next phase of growth as it focuses on developing sacituzumab govitecan in metastatic triple-negative breast cancer, advanced urothelial cancer and other indications of high medical need and on further building its clinical, medical affairs, commercial and manufacturing infrastructure. The royalty rate commences at 4.15 percent on net annual sales of up to $2 billion, declining step-wise based on sales tiers to 1.75 percent on net global annual sales exceeding $6 billion. This transaction will provide sufficient cash to fund operations into 2020.

  • 08

    Jan

IMMU Immunomedics
$15.50

-0.22 (-1.40%)

11/13/17
WELS
11/13/17
NO CHANGE
Target $14
WELS
Outperform
Immunomedics weakness a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough said weakness in Immunomedics is a buying opportunity following review of SABCS abstract data for IIMU132 in TNBC saying he believes the data supports accelerated approval. Birchenough rates Immunomedics an Outperform with a $14 price target.
11/14/17
JEFF
11/14/17
NO CHANGE
Target $16
JEFF
Buy
Jefferies disagrees with yesterday's selloff in Immunomedics
Immunomedics closed down 19% yesterday largely due to interim overall survival data for IMMU-132 and concerns the FDA will require Phase III overall survival data for approval, Jefferies analyst Matthew Andrews tells investors in a research note. The analyst disagrees, and keeps a Buy rating on the shares with a $16 price target. The progression-free survival is the Phase III Special Protocol Assessment's primary endpoint, while the overall survival data may ultimately be confounded by patients' use of other drugs after progression, Andrews tells investors in a research note. Precedent for objective response rate/duration of response exists with FDA breakthrough therapy approvals of 12 solid tumor drugs, some with less robust efficacy than IMMU-132, the analyst adds.
11/14/17
COWN
11/14/17
NO CHANGE
Target $15
COWN
Outperform
Immunomedics drug survival rate disappointing but approval likely, says Cowen
Cowen analyst Phil Nadeau said the overall survival rate for Immunomedics' IMMU-132 showed a decrease, which was disappointing, but the response rate is still well above the current standard of care. As a result, the analyst believes it still appears likely to get accelerated FDA approval. Nadeau reiterated his Outperform rating and $15 price target on Immunomedics shares.
12/06/17
JEFF
12/06/17
NO CHANGE
JEFF
Buy
Immunomedics breast cancer data continue to look 'very solid,' says Jefferies
Jefferies analyst Matthew Andrews says the totality of Immunomedics' Phase II breast cancer data for IMMU-132 "continue to look very solid." Importantly, there was no clinically meaningful decrease in objective response rate per blinded central review, Andrews tells investors in a research note after the company announced updated results. The analyst reiterates a Buy rating and believes the data is sufficient to support FDA accelerated approval.

TODAY'S FREE FLY STORIES

NBL

Noble Energy

$36.85

0.04 (0.11%)

, PES

Pioneer Energy

$5.95

0.3 (5.31%)

08:06
05/24/18
05/24
08:06
05/24/18
08:06
Conference/Events
UBS to hold a conference »

Global Oil & Gas…

NBL

Noble Energy

$36.85

0.04 (0.11%)

PES

Pioneer Energy

$5.95

0.3 (5.31%)

ECA

Encana

$13.34

0.02 (0.15%)

SOI

Solaris Oilfield

$16.46

0.26 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Aug

K

Kellogg

$62.31

0.79 (1.28%)

08:06
05/24/18
05/24
08:06
05/24/18
08:06
Recommendations
Kellogg analyst commentary  »

Kellogg offers attractive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 25

    May

AXDX

Accelerate Diagnostics

$21.05

-0.35 (-1.64%)

08:05
05/24/18
05/24
08:05
05/24/18
08:05
Initiation
Accelerate Diagnostics initiated  »

Accelerate Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

V

Visa

$131.90

1.185 (0.91%)

08:05
05/24/18
05/24
08:05
05/24/18
08:05
Hot Stocks
Visa announces strategic investment in YellowPepper »

Visa announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTM

Tata Motors

$22.39

-0.52 (-2.27%)

08:04
05/24/18
05/24
08:04
05/24/18
08:04
Technical Analysis
Technical Take: Tata Motors down for second session to new 52-week low »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEF

Jefferies Financial Group

$23.47

-0.045 (-0.19%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Hot Stocks
BattleFin names Jefferies as exclusive investment banking partner »

BattleFin announces an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Conference/Events
Deutsche Bank to hold a conference »

Future Metals Corporate…

CEMI

Chembio Diagnostics

$8.70

-0.1 (-1.14%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Hot Stocks
Chembio Diagnostics to commercialize disease tests in Brazil »

Chembio Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

FHB

First Hawaiian

$28.94

0.07 (0.24%)

08:03
05/24/18
05/24
08:03
05/24/18
08:03
Conference/Events
First Hawaiian management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Conference/Events
Jefferies to hold a conference »

Automotive Aftermarket…

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Conference/Events
Morgan Stanley to hold a symposium »

2nd Annual Small &…

MYO

Myomo

$3.28

-0.02 (-0.61%)

08:02
05/24/18
05/24
08:02
05/24/18
08:02
Hot Stocks
Myomo announces MyoPro availability in 16 new U.S. locations »

Myomo announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$29.22

-0.56 (-1.88%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Initiation
Skyline initiated  »

Skyline initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$31.79

-0.08 (-0.25%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Conference/Events
Detroit Economic Club to hold a luncheon »

Tony James, Executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

WHR

Whirlpool

$164.63

0.3 (0.18%)

08:01
05/24/18
05/24
08:01
05/24/18
08:01
Hot Stocks
Whirlpool announces preliminary results of modified Dutch auction tender offer »

Whirlpool Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

HFC

HollyFrontier

$73.67

0.75 (1.03%)

08:00
05/24/18
05/24
08:00
05/24/18
08:00
Recommendations
HollyFrontier analyst commentary  »

HollyFrontier price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$36.72

0.35 (0.96%)

08:00
05/24/18
05/24
08:00
05/24/18
08:00
Options
JD.com call buyer realizes 1% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$144.26

1.36 (0.95%)

07:59
05/24/18
05/24
07:59
05/24/18
07:59
Initiation
Union Pacific initiated  »

Union Pacific resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

NCR

NCR Corp.

$30.75

-0.4 (-1.28%)

07:58
05/24/18
05/24
07:58
05/24/18
07:58
Recommendations
NCR Corp. analyst commentary  »

NCR Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:55
05/24/18
05/24
07:55
05/24/18
07:55
Conference/Events
Federal Reserve Bank of Philadelphia President speaks at a conference »

Philadelphia Federal…

MCRB

Seres Therapeutics

$8.12

0.16 (2.01%)

07:55
05/24/18
05/24
07:55
05/24/18
07:55
Conference/Events
Seres Therapeutics to hold a research and development day »

Microbiome Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Jun

OKTA

Okta

$49.49

0.99 (2.04%)

07:52
05/24/18
05/24
07:52
05/24/18
07:52
Recommendations
Okta analyst commentary  »

Okta price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 06

    Jun

  • 12

    Jun

INTU

Intuit

$196.15

5.74 (3.01%)

07:51
05/24/18
05/24
07:51
05/24/18
07:51
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

CIT

CIT Group

$55.27

-0.06 (-0.11%)

07:51
05/24/18
05/24
07:51
05/24/18
07:51
Hot Stocks
CIT Group announces preliminary results of cash tender offer for common stock »

CIT Group announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDU

New Oriental Education

$101.38

4.82 (4.99%)

07:50
05/24/18
05/24
07:50
05/24/18
07:50
Downgrade
New Oriental Education rating change  »

New Oriental Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.